Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Enzon Pharmaceuticals Inc

+ Add to Watchlist

ENZN:US

0.9627 USD 0.0343 3.44%

As of 20:10:00 ET on 01/30/2015.

Snapshot for Enzon Pharmaceuticals Inc (ENZN)

Open: 0.9900 Day's Range: 0.9500 - 0.9900 Volume: 162,211
Previous Close: 0.9970 52wk Range: 0.7078 - 1.6606 1-Yr Rtn: +17.56%

Stock Chart for ENZN

No chart data available.
  • ENZN:US 0.9600
  • 1D
  • 1M
  • 1Y
0.9970
Interactive ENZN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ENZN

Current P/E Ratio (ttm) 1.4586
Estimated P/E(12/2014) -
Relative P/E vs. SPX 0.0830
Earnings Per Share (USD) (ttm) 0.6600
Est. EPS (USD) (12/2014) -
Est. PEG Ratio -
Market Cap (M USD) 42.50
Shares Outstanding (M) 44.14
30 Day Average Volume 151,321
Price/Book (mrq) 1.5059
Price/Sale (ttm) 1.3112
Dividend Indicated Gross Yield -%
Cash Dividend (USD) 0.1000
Dividend Ex-Date 01/08/2015
5 Year Dividend Growth -
Next Earnings Announcement 03/13/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ENZN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ENZN

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company has developed several products, including PEG-INTRON. Enzon's product-focused strategy includes a drug development program that leverages its PEG modification and single-chain antibody (SCA) technologies.

George W Hebard IIIInterim COO/SecretaryRichard L FeinsteinVP:Finance/Principal Financial Ofcr
More Company Profile & Key Executives for ENZN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil